Core Viewpoint - Fosun Pharma has signed a licensing agreement with Pfizer for the development and commercialization of GLP-1R agonists, including YP05002, for various therapeutic applications globally [1] Group 1: Licensing Agreement Details - The agreement grants Pfizer exclusive rights to develop, use, produce, and commercialize the GLP-1R agonist products in all therapeutic areas for humans and animals [1] - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, will receive an upfront payment of $15 million and potential milestone payments up to $35 million based on clinical and commercialization progress [1] Group 2: Product and Market Potential - YP05002 is aimed at treating metabolic-related diseases, with potential indications including long-term weight management, type 2 diabetes, and non-alcoholic steatohepatitis [1]